Securities code: Cansino Biologics Inc(688185) securities abbreviation: Cansino Biologics Inc(688185) Announcement No.: 2022030 Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
About recombinant novel coronavirus vaccine (adenovirus type 5 vector)
Announcement of being included in the World Health Organization (who) emergency use list
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
1、 Overview
The World Health Organization (hereinafter referred to as “who”) posted on its official website on May 19, 2022（ https://www.who.int/news/item/19-052022-who-validates-11th-vaccine-for-covid-19 ）It is disclosed that the recombinant novel coronavirus vaccine (adenovirus type 5 vector) of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) .
The product is constructed by genetic engineering method. With replication defective human type 5 adenovirus as the vector, it can express the S antigen of novel coronavirus. It is intended to prevent diseases caused by novel coronavirus infection. At the same time, it does not contain preservatives, adjuvants and ingredients of animal origin.
2、 Specific situation
The Eul procedure assesses the suitability of new health products in public health emergencies. Its purpose is to provide drugs, vaccines and diagnostic methods as soon as possible in response to emergencies, while respecting strict safety, efficacy and quality standards. The assessment process should weigh the threat posed by the emergency, the benefits of using the product and any potential risks. At the same time, who Eul is a prerequisite for providing vaccines for covid-19 vaccine implementation plan (covax). The list also allows countries to accelerate their respective regulatory approvals to import and manage covid-19 vaccines. The decision to include kweisa in Eul is based on the review of the product’s quality, safety, effectiveness data and risk management plan (RMP) by who prequalification (PQ) experts, including regulatory experts from around the world. The final risk benefit assessment is conducted by the Eul technical advisory group (tag).
3、 Impact on the company
After the product is included in who Eul, the company still needs to conduct commercial negotiations with the intended countries on the future sales of the product. If the subsequent overseas countries increase the purchase and use of the product, it will have a certain positive impact on the performance of the listed company.
4、 Risk tips
1. Thanks to the efforts of the World Health Organization (who) and countries around the world, the global covid-19 vaccination population will increase rapidly in 2021 and is expected to maintain an upward trend in 2022. However, it will be more difficult to promote covid-19 vaccination in the future, and the growth rate of global covid-19 vaccination rate will gradually slow down. With more covid-19 vaccine products on the market, the market competition will become more intense. At the same time, the future market sales of this product will also be affected by the development and changes of the epidemic situation and other factors.
2. Please make careful decisions and pay attention to preventing investment risks. The information about the company shall be subject to the announcements published in China Securities News, securities times, Securities Daily, Shanghai Securities News and the website of Shanghai Stock Exchange.
It is hereby announced.
Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) board of directors may 20, 2022
